SPOTLIGHT DISCUSSION - Rare diseases – under the microscope

Tuesday, November 17, 2020 2:30 PM to 3:05 PM


  • Do current incentives match the difficulties companies face when developing orphan drugs? And is the reward proportionate to the benefits?
  • Is there a balance between the value of new orphan drugs and the cost? 
  • What is the role of public investment in answering unmet needs? 
  • Is there a risk the regulation developed for orphan drugs become the rule?